‘Fierce new drugs,’ Belviq and Xtandi, reserved to be blockbusters

Recently-launched new products have shown smooth starts. In particular, Belviq, an obesity treatment, and ‘Xtandi,’ a prostate cancer treatment, have already notified the market of becoming KRW 10 billion blockbusters.

According to the Medipana News’s analysis result of sales performance of recently-launched new products based on the IMS Health data, ‘Eylea,’a Bayer Korea’s second-year macular...